Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Optomed

1.59 EUR-0.99 %10.9, 17.29
5,673 following

OPTOMED

NASDAQ Helsinki

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
-0.99 %
-3.28 %
+10.54 %
-36.75 %
-57.72 %
-57.49 %
-48.08 %
-87.92 %
-65.20 %

Optomed operates in the medical technology sector. The company conducts research and development of specialized eye cameras. Development takes place of both hardware and software that are resold under different brands. Operations are held on a global level, with the largest presence in the Nordic market. Customers consist of research institutes and hospitals. The company has its headquarters in Oulu.

Read more
Market cap
34.26M EUR
Turnover
38.14K EUR
P/E (adj.) (26e)
-12.59
EV/EBIT (adj.) (26e)
-9
P/B (26e)
1.6
EV/S (26e)
1.67
Dividend yield-% (26e)
-
Coverage
Recommendation
Accumulate
Target price
2.00 EUR
Updated
17.08.2026
Disclaimer
Juha Kinnunen
Juha Kinnunen

Analyst

Latest research

Latest analysis report

Released: 17.08.2026

Revenue and EBIT-%
EPS and dividend
Financial calendar
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
ShowingAll content types

Forum discussions
[quote=“Clark_kent, post:6761, topic:2389”] No one has yet explained to me who this product (handheld camera + AI) is supposed to be sold to (in the US). [/quote> In Finland, it’s worth taking a close look at what Terveystalo achieves with its Synsam acquisition. I’ll improvise a...
22 hours ago
by Dr.Feelgood
15
Isn’t it precisely the case that if the algorithm raises an alarm, you then go to a real doctor for a diagnosis on how that diabetes has actually started developing in the retina? Therefore, as a patient, you can feel quite confident when the algorithm is tuned to be sensitive.
yesterday
by Puutaheinää
6
Do you have any idea who the desktop camera + AI is supposed to be sold to in the USA?
23 hours ago
by Puutaheinää
3
Yeah, I composed that from memory and mixed up Synsam and Silmäasema. The scenario remained the same, though: screening imaging is trickling out of specialized medical care thanks to AI.
10 hours ago
by Dr.Feelgood
2
Some guys from Optomed are involved as authors in this brand new science article… can anyone open it, what can be deduced from the article? https://www.nature.com/articles/s41598-026-70676-2
13 hours ago
by Puutaheinää
2
Everyone who lacks the ophthalmological qualifications to give a diagnosis is a customer for the product. This specifically acts as a tough tool for ophthalmologists and screens out those negative cases with a 99% accuracy.
23 hours ago
2
Not really. As long as insurance companies accept lobbying from doctors that they must be allowed to examine everything themselves, what’s going to change in the setup? In the most sensibly implemented healthcare systems, AI screening will likely be implemented within a few years...
23 hours ago
by Clark kent
1
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.11
2026

Interim report Q3'26

18.2
2027

Annual report '26

4.5
2027

Interim report Q1'27

Optomeds dattercelskab Ubetec har vundet Veikkauses udbud
Analyst Comment07.09.2026, 06.55 by
Juha Kinnunen

Optomeds dattercelskab Ubetec har vundet Veikkauses udbud

Veikkaus' kontraktsejr på 0,9 MEUR styrker datterselskabet Ubetecin position på det åbne finske spillegældsmarked.

Optomed
Regulatory press release04.09.2026, 14.00

Optomed Oyj: Composition of Optomed's Shareholders' Nomination Board

Optomed
Press release18.08.2026, 13.10

Redeye: Optomed (Q2 Review): Sales miss offset by strong gross margin and cost control

Optomed

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Optomed Q2'26: Salget af udstyr halter, men de løbende indtægter vokser
Research17.08.2026, 07.00 by
Juha Kinnunen

Optomed Q2'26: Salget af udstyr halter, men de løbende indtægter vokser

Optomeds omsætning og resultat i 2. kvartal lå markant under vores forventninger, da salget af udstyr fortsat var trægt. Det positive i regnskabsmeddelelsen var den fortsatte vækst i Aurora AEYE-salget, reducerede omkostninger, en tydeligt forbedret pengestrøm og en rekordhøj bruttofortjeneste.

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Tauriainen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Leppänen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Wen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Salonen

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Lee

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Calarco

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Badlani

Optomed
Regulatory press release14.08.2026, 12.00

Optomed Plc - Managers' transactions - Mäkinen

Optomed
Regulatory press release14.08.2026, 08.30

Optomed Oyj: Directed share issue without payment to implement Board remuneration

Optomed
Regulatory press release14.08.2026, 08.30

Optomed Oyj: Optomed's financial reporting in 2027

Optomed
Regulatory press release14.08.2026, 08.00

Optomed Plc: Half-year report January - June 2026

Optomed
Optomed Q2'26 preview: Vi forventer tilbagevenden til vækst og overvåger pengestrømmen
Analyst Comment11.08.2026, 07.02 by
Juha Kinnunen

Optomed Q2'26 preview: Vi forventer tilbagevenden til vækst og overvåger pengestrømmen

Vi estimerer, at omsætningen er steget, efterhånden som salget af udstyr er kommet sig efter et svagt første halvår.

Optomed
Press release23.06.2026, 09.43

Redeye: Optomed: Solid device order

Optomed
Optomed modtog en udstyrsordre på 1,8 MEUR fra USA
Analyst Comment22.06.2026, 06.58 by
Atte Riikola

Optomed modtog en udstyrsordre på 1,8 MEUR fra USA

Ordren overstiger hele årets første halvårs omsætning for udstyr og styrker pengestrømmen.

Optomed
Regulatory press release18.06.2026, 16.30

Inside Information: Optomed receives a large order in the US

Optomed
Press release11.05.2026, 15.16

Redeye: Optomed (Q1 Interview): Expecting normalised sales in upcoming quarters

Optomed